What Is Happening With HCA Healthcare Stock?
HCA Healthcare (HCA)’s stock skyrocketed over 50%, fueled not just by steady revenue and margin gains, but a stunning leap in investor optimism. Behind the surge: a string of earnings beats, upbeat guidance, and fresh analyst praise, all spotlighted at the recent UBS conference. Let’s unpack the story driving this rally.
| 2152025 | 11122025 | Change | |
|---|---|---|---|
| Stock Price ($) | 314.3 | 473.6 | 50.7% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 70,603.0 | 72,698.0 | 3.0% |
| Net Income Margin (%) | 8.2% | 8.2% | 0.7% |
| P/E Multiple | 13.8 | 19.0 | 37.9% |
| Shares Outstanding (Mil) | 252.1 | 239.2 | 5.1% |
| Cumulative Contribution | 50.3% |
So what is happening here? The stock jumped 51%, driven by a 3.0% revenue boost, a 0.7% margin lift, and a huge 38% surge in the P/E multiple. Let’s dig into what’s behind these numbers.
Before we get into details of events that led to stock surge, here is what market wisdom says: A single stock can be risky, but there is a huge value to a broader, diversified approach we take with the Trefis High Quality Portfolio. Trefis works with Empirical Asset Management — a Boston area wealth manager — whose asset allocation strategies yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Empirical has incorporated the Trefis HQ Portfolio in this asset allocation framework to provide clients with higher returns while taking on lower levels of risk versus the benchmark index.
Here Is Why HCA Healthcare Stock Moved
- Robinhood Stock: The Multiple Tells The Wrong Story
- How ISRG Just Secured The U.S. Market
- How UNH Stock Is Trading Short-Term Margins For Long-Term Moats
- Key Metrics To Track For Capital One After Its Q1 Earnings Miss
- Marvell Stock: The Good News Keeps Coming
- Fifth Third Earnings: Adjusted EPS Beats Despite Revenue Miss And Acquisition.
- Q1 2025 Earnings Beat: HCA reported strong Q1 2025 financial results, exceeding analyst profit expectations and reaffirming 2025 guidance.
- Q2 2025 Earnings & Guidance: Q2 results beat estimates, and full-year 2025 guidance was raised. Shares initially fell slightly.
- Q3 2025 Strong Results: Q3 2025 earnings and revenues topped estimates, with updated higher 2025 guidance.
- Analyst Sentiment: Analysts maintained a ‘Buy’ consensus rating and issued updated price targets with upside.
- UBS Conference Insights: Presented strategic insights, including AI integration and future plans, at a healthcare conference.
Our Current Assesment Of HCA Stock
Opinion: We currently find HCA stock fairly priced. Why so? Have a look at the full story. Read Buy or Sell HCA Stock to see what drives our current opinion.
Risk: To get a handle on HCA’s risk, check how far it fell in past market crashes. During the 2018 correction, it dropped about 23%. The Covid pandemic hit much harder, with a sharp 55% decline. Then the inflation shock pulled it down nearly 40%. These dips show that even with solid fundamentals, HCA isn’t immune to significant pullbacks when broader markets get rattled. Good quality stocks help, but big shocks still take a toll.
HCA stock may have seen strong gains recently, but investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.